Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott HIV-1 protease inhibitor

Executive Summary

Abbott's A-74704 "inhibits both protease activity and acute HIV-1 infection in vitro," company scientists John Erickson and colleagues report in the Aug. 3 issue of Science. Abbott says its protease inhibitor's symmetrical shape differs from other agents under study. Since the active site of HIV protease also has a symmetrical molecular structure, "symmetrical protease inhibitors should be able to effectively 'lock' into the active site of HIV protease," Abbott says. Merck, Upjohn, and SmithKline are among other firms developing protease inhibitors.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts